Keywords: Genmab, GlaxoSmithKline, Arzerra, FDA approval, Licensing
FDA approval of Arzerra triggers $23 million milestone for Genmab from GSK
Article | 27 October 2009
The US Food and Drug Administration has approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
